SIRPA and Thrombocytopenia: While targeting SIRPα has shown success in eliminating the thrombocytopenia associated with CD47-targeting agents, the strategy still presents a risk through potential binding of these antibodies to SIRPβ and SIRPγ, which have high sequence homology to SIRPα in the extracellular domain [16].